Physician profile
Glenda Read
NPI 1518030212
$591.23
in general payments reported to CMS, 2019-2025
13 companies · $15.27 in 2025
The $15.27 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $98.11 · 2021: $48.99 · 2022: $91.82 · 2023: $90.87 · 2025: $15.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $123.76 | 2019-2025 | |
| Lucid Diagnostics INC. | $91.82 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $60.93 | 2019-2023 | Farxiga |
| Medtronic Vascular, INC. | $59.57 | 2019 | |
| Glaxosmithkline, LLC. | $43.06 | 2019-2023 | Shingrix, Bexsero |
| Janssen Pharmaceuticals, INC | $38.51 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $37.83 | 2020 | |
| Dexcom, INC. | $27.41 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $27.21 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $22.74 | 2021 | |
| Abbott Laboratories | $21.77 | 2023 | Freestyle Libre 3 |
| Abbvie INC. | $20.95 | 2023 | |
| Shire North American Group INC | $15.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenda Read listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.